Semnur Pharmaceuticals, Inc.
Close on Oct 19, 2026
- Market cap
- $98.30M
- P/E (TTM)
- –
- Dividend yield
- –
About Semnur Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
Semnur Pharmaceuticals is a clinical-stage biopharmaceutical firm that develops non-opioid therapeutics for acute and chronic pain conditions. The company focuses on addressing conditions with high unmet medical needs through non-addictive pain relief alternatives. Its primary pipeline candidate is SP-102, an injectable corticosteroid viscous gel formulated without preservatives, surfactants, solvents, or particulates. This therapy is designed for epidural administration to relieve discomfort in individuals experiencing sciatica, also known as lumbar radicular pain. Through its development programs, the company targets adult patients suffering from nerve-related back pain who require interventional medical treatment.
The enterprise is incorporated in Delaware and maintains its principal executive offices in Palo Alto, California. Its clinical research and development operations take place within the United States, where it conducts multi-center clinical trials across domestic study sites.
Summary of the business section of Semnur Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Semnur Pharmaceuticals, Inc.
- Founded
- 2013
- Headquarters
- Palo Alto, CA
- Address
- 960 San Antonio Road 94303
- Phone
- (650) 516-4310
- Website
- semnurpharma.com
- Employees
- 10, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PIPARA & CO LLP, New Delhi, India
Stock & identifiers
- Ticker
- SMNR
- Other tickers
- SMNRW
- Exchange
- OTC
- IPO date
- Sep 23, 2025
- Shares outstanding
- 230M, Aug 10, 2026
- Public float
- $500.00K, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1913577
- CUSIP
- 81686G105
- ISIN
- US81686G1058
- LEI
- 549300L7MIQ7V1UUZB95
- EIN
- 98-1659463
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Henry Ji | Executive Chairperson, Director | – |
| Jaisim Shah | See Remarks, Director | – |
| Stephen Hoi Ma | See Remarks | – |
| Annu Navani | Director | – |
| Dorman Followwill | Director | – |
| Yue Alexander Wu | Director | – |
| Jay Chun | Director | – |
Corporate history
Events identified from SEC filings